ETNB - 89bio Inc
IEX Last Trade
9.5
0.270 2.842%
Share volume: 389,178
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$9.23
0.27
2.93%
Fundamental analysis
27%
Profitability
25%
Dept financing
25%
Liquidity
50%
Performance
25%
Performance
5 Days
7.28%
1 Month
4.51%
3 Months
22.11%
6 Months
-19.22%
1 Year
-44.25%
2 Year
123.53%
Key data
Stock price
$9.50
DAY RANGE
N/A - N/A
52 WEEK RANGE
$6.58 - $18.25
52 WEEK CHANGE
-$0.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO:
Region: US
Website: 89bio.com
Employees: 45
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: 89bio.com
Employees: 45
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
Recent news